NCT02893111View on ClinicalTrials.gov

Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 25, 2016

Study Completion Date

January 31, 2017

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Bortezomib

Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT02893111 - Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter